C-C Chemokine receptor 8 (CCR8) immune pathway
Guided by a deep understanding of causal human biology, scientists at Bristol Myers Squibb study the tumor microenvironment (TME), the protective environment surrounding cancer cells, and work to match the right therapeutic modality to the underlying biological mechanism, an approach applied across the company’s broader work in oncology research.
With these principles in mind, researchers at Bristol Myers Squibb are investigating the C-C motif chemokine receptor 8 (CCR8) pathway to find new ways to treat solid tumors by engaging the body’s own immune system.
Download the fact sheet for a complete overview of the CCR8 immune pathway and how Bristol Myers Squibb is investigating it in solid tumors.
What you should know
- CCR8 is a marker found on a type of immune cell called a Treg, short for regulatory T cell. Tregs act as a built-in “brake” on effector T cells – the immune system’s cells responsible for recognizing and eliminating abnormal cells, including cancer.
- Tumors build up especially after high numbers of CCR8-marked Tregs within the TME, which is a protective area surrounding cancer cells, and use these Tregs to limit effector T-cell activity in that space.
- Researchers at Bristol Myers Squibb are looking at whether targeting these TME-based Tregs can restore effector T-cell activity against the tumor.
Get the full overview
Download the CCR8 fact sheet for the complete pathway overview.